Structure Therapeutics, Inc. Sponsored ADR ( (GPCR)) has released its Q3 earnings. Here is a breakdown of the information Structure Therapeutics, Inc. Sponsored ADR presented to its investors.
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results